---
description: System and Environment
---

# Immunotherapy

> [**PDFs**](https://cloud.tsinghua.edu.cn/d/07d2b19d6b284ebea5ea/?p=%2F1.%20Precision%20Medicine\&mode=list)
>
> ✅ **: recommended readings**

## **1. dsRNA in immunology**

* \[review] **2019 noncoding RNA** - Endogenous Double-Stranded RNA
* ✅  **2022 Nature Review - Mol Cell Biol.** - Cellular origins of dsRNA, their recognition and consequences
* [**2021 Cancer Discovery** ](https://aacrjournals.org/cancerdiscovery/article/11/3/638/3342/Aggressive-PDACs-Show-Hypomethylation-of)- Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell of Origin
* **2022 Nature Reviews Immunology** - The roles of extracellular vesicles in the immune system
* _**2022 Immunity**_ - Distinct and Orchestrated Functions of RNA Sensors in Innate Immunity
* _**2021 Genome Biology**_ - Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways
* _**2018 - JCO**_ - Immune checkpoint molecule expression measured using circulating cell-free RNA isolated from the blood of metastatic prostate cancer patients.
* ✅  **2016 Cell Host & Microbe** - The Evolution of Antiviral Defense Systems

### 1.1 ncRNA and immune

* \[review] **2022 Journal of Autoimmunity** - Evolving understandings for the roles of non-coding RNAs in autoimmunity and autoimmune disease
* \[review] **2022 Journal of Autoimmunity** - Non-coding RNAs in immunoregulation and autoimmunity: Technological advances and critical limitations
* \[srpRNA] **2021 **_**Cell**_ - The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function
* ✅  \[srpRNA] _**2017 Cell**_ - Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer
* **2012 Nature Reviews Rheumatology** - MicroRNAs—novel regulators of systemic lupus erythematosus pathogenesis

### 1.2 RNA editing and immune

* ✅  [**2022 Nature**](https://www.nature.com/articles/s41586-022-05052-x) - RNA editing underlies genetic risk of common inflammatory diseases
* [**2022 Cancer Res.**](https://doi.org/10.1158/0008-5472.can-22-1062) - Single-cell analysis in lung adenocarcinoma implicates RNA editing in cancer innate immunity and patient prognosis
* **2020 Genome Biology** - Human A-to-I RNA editing SNP loci are enriched in GWAS signals for autoimmune diseases and under balancing selection
* [**2018 Cell** ](https://www.cell.com/cell/fulltext/S0092-8674\(17\)31518-0?\_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867417315180%3Fshowall%3Dtr)- Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown

### 1.3 RNA modification and immune

* **2022 Nature Methods** - Multiplexed profiling facilitates robust m6A quantification at site, gene and sample resolution
* **\[review] 2023 Trends in Immunology** - ‘(m 6 )A’ stands for ‘autoimmunity’: reading, writing, and erasing RNA modiﬁcations during inﬂammation
* ✅ [**2020 Immunity**](https://www.sciencedirect.com/science/article/pii/S1074761320301849)  - m6A Modification Prevents Formation of Endogenous Double-Stranded RNAs and Deleterious Innate Immune Responses during Hematopoietic Development

### 1.4. dsRNA identification and prediction

* **2023 BioRxiv** - dsRID: Editing-free in silico identification of dsRNA region using long-read RNA-seq data



## **2. Methods**

* _**2019 - Nat Genetics**_ - Landscape of B cell immunity and related immune evasion in human cancers. PubMed PMID: 30742113
* _**2016 - Nature Genetics**_ - Landscape of tumor-infiltrating T cell repertoire of human cancers
* _**2018 - Nat Biotech**_ - Evaluation of immune repertoire inference methods from RNA-seq data. PubMed PMID: 30412202

## **3. Applications**&#x20;

### **Immune Diseases**

* **\[review] 2023 Nature Reviews Rheumatology** - Precision medicine in systemic lupus erythematosus
* **\[review] 2022 Nature Reviews Rheumatology** - The role of mitochondria in rheumatic diseases
* **2022 Nature Leukemia** - Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction
* [**2022 **_**Signal transduction and targeted therapy**_](https://www.nature.com/articles/s41392-022-01167-9) - Deciphering transcriptome alterations in bone marrow hematopoiesis at single-cell resolution in immune thrombocytopenia
* ✅ (SLE biomarker) [_**2022 Lancet Rheumatol**_](https://www.sciencedirect.com/science/article/pii/S2665991322003320?via%3Dihub) - Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial
* [**2022 **_**Cell Reports**_](https://pubmed.ncbi.nlm.nih.gov/36351407/) - Single-cell transcriptome profiling and chromatin accessibility reveal an exhausted regulatory CD4+ T cell subset in systemic lupus erythematosus
* ✅ [**2022 **_**Science**_](https://pubmed.ncbi.nlm.nih.gov/35389781/) - Single-cell RNA-seq reveals cell type–specific molecular and genetic associations to lupus
* ✅ [**2022 **_**Cell**_](https://www.sciencedirect.com/science/article/pii/S0092867422009242) _**-**_ Distinct transcriptome architectures underlying lupus establishment and exacerbation
* ✅ [**2021 **_**Cell**_ ](https://pubmed.ncbi.nlm.nih.gov/33930287/)- Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases
* [**2022 Nature Med**](https://www.nature.com/articles/s41591-022-01789-0) - Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
* 2021 PNAS - The dynamic epigenetic regulation of the inactive X chromosome in healthy human B cells is dysregulated in lupus patients
* **2020 Nature Immunology** - Mapping systemic lupus erythematosus heterogeneity at the single-cell level
* ✅ [**2019 **_**Nature**_](https://pubmed.ncbi.nlm.nih.gov/31554970/) - Analysis of the B cell receptor repertoire in six immune-mediated diseases

### **Cancer Immunotherapy**

* **2023 Cancer Cell** - The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients
* (neoadjuvant biomarker) [_**2022 Mol. Cancer**_ ](https://doi.org/10.1186/s12943-022-01684-9)- A liquid biopsy signature of circulating exosome-derived mRNAs, miRNAs and lncRNAs predict therapeutic efficacy to neoadjuvant chemotherapy in patients with advanced gastric cancer
* ✅ (neoadjuvant) **2022 **_**Cell**_ - Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy
* (neoadjuvant) **2022 Nature Med  -** Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
* (non-neo adjuvant) **2021** _**Nature -**_ ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
* **2020 Science Advance** - Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy

## 4. Neoantigen

* \[review] _**2021 Nature**_ - Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
* \[review] _**2017 Cell**_ - Applications of Immunogenomics to Cancer
* _**2020 NCOMM**_ - Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate

## 5. RNA Vaccine

* **2023 Cell** - Delivering the next generation of cancer immunotherapies with RNA
